Top 10 Suvorexant (Belsomra) Generic Manufacturers in USA
The pharmaceutical market for sleep aids, particularly drugs like Suvorexant (brand name Belsomra), has seen significant growth in recent years. With the increasing prevalence of sleep disorders, the demand for effective treatment options has risen sharply. In the USA alone, the sleep aid market size was estimated to be around $5 billion in 2022, with a projected growth rate of 7.1% CAGR through 2030. As patent exclusivity for drugs like Suvorexant wanes, generic manufacturers are stepping in to capture market share, creating a competitive landscape enriched with innovation and affordability.
1. Teva Pharmaceutical Industries
Teva is one of the largest generic pharmaceutical companies globally, with a market share of approximately 10% in the US generics market. They have consistently produced high-quality generics, including Suvorexant, contributing to an annual revenue of over $16 billion.
2. Mylan N.V. (now part of Viatris)
Mylan, now part of Viatris, has a robust portfolio of generic medications, including Suvorexant. The company holds around 5% of the US generic market share, producing over 1,500 generic products, which generate approximately $11 billion in annual sales.
3. Sandoz (a Novartis division)
Sandoz is a leading generic pharmaceutical company that manufactures Suvorexant, contributing to its diverse portfolio of over 1,000 products. With a market share of about 4%, Sandoz reported sales of approximately $10 billion in 2022.
4. Amgen Inc.
While primarily known for biologics, Amgen has expanded into generics and produced Suvorexant. The company boasts a significant market presence with revenues of over $25 billion, reflecting its investment in diversifying its portfolio.
5. Hikma Pharmaceuticals
Hikma is a key player in the generic market, particularly in the USA, where it has a market share of approximately 3%. The company’s production of Suvorexant is part of a larger strategy to offer competitive pricing in the $5 billion sleep aid market.
6. Aurobindo Pharma
Aurobindo is known for its wide-ranging generic offerings, including Suvorexant. The company’s market share in the US is about 2.5%, with total sales crossing the $2 billion mark, showcasing its growth trajectory in the generics space.
7. Lupin Pharmaceuticals
With a focus on generics and specialty drugs, Lupin Pharmaceuticals has made significant inroads into the US market, holding a market share of roughly 2%. Their production of Suvorexant is a testament to their commitment to addressing sleep disorders.
8. Sun Pharmaceutical Industries
Sun Pharma has established a firm foothold in the US generic market, with an estimated 1.5% market share. The company aims to provide affordable access to medications like Suvorexant, contributing to its annual revenue of approximately $5 billion.
9. Endo International plc
Endo has diversified its portfolio with a range of generic products, including Suvorexant. The company holds around 1.3% of the US market share, generating revenues of about $2.5 billion, which reflects its strategy to penetrate the sleep aid segment.
10. Zydus Cadila
Zydus Cadila is gaining traction in the US generics market with a focus on high-quality medications. The company produces Suvorexant and holds about 1% of the market share, contributing to its overall revenue of approximately $2 billion.
Insights
The generic market for Suvorexant is evolving, with manufacturers increasingly focusing on high-quality production and competitive pricing to capture market share. According to the FDA, the number of approved generic drugs has increased by nearly 25% over the past five years, facilitating greater access to affordable medications. As the sleep aid market continues to grow, projected to reach $8 billion by 2030, generic manufacturers will play a pivotal role in meeting the rising demand while maintaining stringent quality standards. The ongoing trend towards consolidation in the pharmaceutical industry may further impact competition and innovation in this sector.
Related Analysis: View Previous Industry Report
